paclitaxel has been researched along with Diarrhea in 92 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (11.96) | 18.2507 |
| 2000's | 42 (45.65) | 29.6817 |
| 2010's | 35 (38.04) | 24.3611 |
| 2020's | 4 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, X; Guan, J; Lin, Y; Mao, F; Pan, B; Peng, L; Shen, S; Sun, Q; Wang, C; Wang, X; Xu, C; Xu, Y; Yao, R; Zhang, X; Zhang, Y; Zhong, Y; Zhou, X; Zhou, Y | 1 |
| Chen, Z; Jiang, Y; Song, B | 1 |
| Dilawari, A; Graham, D; Isaacs, C; Kurian, S; Lynce, F; Mainor, C; McNamara, D; Mohebtash, M; Ottaviano, Y; Pohlmann, PR; Rao, S; Swain, SM; Swanson, N; Tan, M; Warren, R; Wu, T | 1 |
| Arima, S; Fukahori, M; Honda, T; Ide, Y; Ido, A; Kawahira, M; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Ueda, Y; Ureshino, N | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Ahn, MJ; Barlesi, F; Fadeeva, N; Ganea, DE; Gonzalez Mella, PF; Govindan, R; Han, B; Jassem, J; Kopit, J; Kurata, T; Lee, KH; Li, M; O'Byrne, K; Postmus, PE; Reck, M; Schneider, CP; Szczesna, A; Tamura, T; Tschaika, M; Vladimirov, V; Von Pawel, J; Zhang, L | 1 |
| Christofillakis, C; Georgoulias, V; Kalbakis, K; Kentepozidis, N; Kourousis, C; Mavroudis, D; Nikolaou, M; Pistamaltzian, N; Polyzos, A; Saloustros, E; Vamvakas, L | 1 |
| Adessi, C; Albanell, J; Cejalvo, JM; Ceppi, M; Cervantes, A; Cortés, J; Dieras, V; Gonzalez, I; Hasmann, M; Jacob, W; James, I; Joly, F; Lassen, U; Levy, C; Lopez-Martin, J; Marmé, F; Martinez-Garcia, M; May, M; Meneses-Lorente, G; Michielin, F; Moisan, A; Park-Simon, TW; Racek, T; Schindler, C; Schneeweiss, A; Weisser, M; Welt, A | 1 |
| Anderson, B; Nehra, V; Yasir, S | 1 |
| Adessi, C; Dang, JS; Laurent, J; McIntyre, C; Meneses-Lorente, G; Mercier, F; Ravva, P; Xu, C | 1 |
| Cresta, S; Damian, S; Gendreau, S; Mayer, IA; Morrissey, KM; Ng, VW; Rooney, I; Schöffski, P; Singel, SM; Spoerke, JM; Wildiers, H; Winer, E | 1 |
| Cartagena-Albertus, JC; Engel Manchado, J; Moise, A; Montoya Alonso, JA; Moya García, S | 1 |
| Beckmann, M; Du Bois, A; Eidtmann, H; Heilmann, V; Hubalek, M; Huober, J; Jackisch, C; Loibl, S; Lück, HJ; Richter, B; Schrader, I; Schuster, T; Stähler, A; Stickeler, E; Thomssen, C; Untch, M; von Minckwitz, G; Wollschläger, K | 1 |
| Agbor-Tarh, D; Aktas, B; Azim, HA; Baselga, J; Bradbury, I; de Azambuja, E; Di Cosimo, S; Dinh, P; Dreosti, L; Eidtmann, H; Greger, JG; Hsieh, RK; Huang, CS; Jackisch, C; Kim, SB; Piccart, M; Smith, I; Vuylsteke, P | 1 |
| Hei, YJ; Hsia, TC; Ichinose, Y; Kim, JH; Kim, SW; Kubota, K; Li, RK; Lim, WT; Park, K; Scagliotti, G; Shinkai, T; Spigel, D; Takeda, K; Tiangco, BJ; Yao, B; Yau, S | 1 |
| Chen, L; Chen, Q; Chen, Z; Shen, L; Shen, X; Tao, J; Wang, H; Wang, J; Zhang, Y; Zhu, M; Zhuang, Z | 1 |
| Doerr, M; Kim, J; Kitchell, BE | 1 |
| Bateman, E; Bowen, JM; Boyle, FM; Keefe, DM; Mayo, BJ; Plews, E; Stringer, AM; Wignall, A | 1 |
| Abdulaal, Y; Gooneratne, AT; Gupta, J; James, AO | 1 |
| Aogi, K; Armour, A; Inoue, K; Iwata, H; Kuroi, K; Masuda, N; Nakayama, T; Nishimura, Y; Rai, Y; Sasaki, Y; Shimizu, S | 1 |
| Koo, YJ; Lim, KT | 1 |
| Bidziński, M; Bjørge, L; Colombo, N; de Gregorio, N; Del Campo, JM; Denison, U; du Bois, A; Harter, P; Heubner, M; Hilpert, F; Kristensen, G; Lortholary, A; Malander, S; Meier, W; Merger, M; Minarik, T; Mirza, MR; Nicoletto, MO; Ottevanger, P; Pfisterer, J; Pignata, S; Ray-Coquard, I; Reuss, A; Sailer, MO; Scambia, G; Sevin, E; Vergote, I | 1 |
| Dezentjé, VO; Honkoop, AH; Kemper, I; Linn, SC; Mandjes, IA; Oving, IM; Smorenburg, CH; Sonke, GS; Stouthard, JM; van Ramshorst, MS; van Werkhoven, E | 1 |
| Gao, JJ; Pohlmann, PR; Swain, SM; Tan, M | 1 |
| Arita, KI; Doi, M; Hattori, N; Kitaguchi, S; Kondo, T; Murakami, I; Nakano, K; Sakurai, J; Yamasaki, M | 1 |
| Goense, L; Haj Mohammad, N; Meijer, GJ; Mook, S; Ruurda, JP; van der Horst, S; van der Sluis, PC; van Hillegersberg, R; van Rossum, PSN; van Vulpen, M | 1 |
| Bedikian, AY; Homsi, J; Hwu, P; Hwu, WJ; Kim, KB; Mahoney, SL; Papadopoulos, NE | 1 |
| Bekele, NB; Carter, CM; Mathew, P; Pagliaro, L; Tannir, N; Tu, SM | 1 |
| Díaz-Rubio, E; López-Tarruella, S; Manzano, A; Martin, M; Puente, J | 1 |
| Abbruzzi, A; Chen, C; Come, S; Dang, C; Hudis, C; Lin, N; Morris, P; Moy, B; Norton, L; Patil, S; Steingart, R; Sugarman, S; Winer, E | 1 |
| Grigsby, PW; Schwarz, JK; Wahab, S | 1 |
| Liu, S; Pan, T; Wang, MK; Wang, S; Zhang, DS | 1 |
| Amin, P; Bridges, B; Dawson, N; DiBiase, S; Engstrom, C; Goloubeva, O; Hussain, A; Kwok, Y; Mannuel, H; Mirmiran, A; Wu, Y | 1 |
| Bethke, K; Cianfrocca, M; Gordon, J; Gradishar, W; Hansen, N; Jeruss, JS; Jovanovic, B; Kaklamani, VG; Khan, SA; Lacouture, M; Meservey, C; Parimi, V; Rosen, S; Scholtens, D; Siziopikou, K; Uthe, R; Von Roenn, J; Wayne, J | 1 |
| Ando, M; Fujiwara, Y; Hashimoto, K; Hirata, T; Katsumata, N; Shimizu, C; Tamura, K; Yamamoto, H; Yonemori, K; Yunokawa, M | 1 |
| Aktan, G; Aura, C; Baselga, J; Bradbury, I; Chang, TW; Coccia-Portugal, M; de Azambuja, E; Di Cosimo, S; Dinh, P; Domont, J; Eidtmann, H; Fauria, K; Gelber, RD; Goldhirsch, A; Gómez, H; Horváth, Z; Kunz, G; Lerzo, G; Palacova, M; Piccart-Gebhart, M; Probachai, V; Pusztai, L; Semiglazov, V; Sohn, JH; Tseng, LM; Untch, M; Van Dooren, V | 1 |
| Ball, M; Chester, J; Coffey, M; Gore, ME; Hall, GD; Harrington, KJ; Karapanagiotou, EM; Larkin, J; Melcher, AA; Mettinger, K; Newbold, K; Nutting, C; Pandha, HS; Roulstone, V; Syrigos, KN; Tanay, M; Thompson, B; Twigger, K; Vile, RG | 1 |
| Bateman, E; Bowen, JM; Boyle, FM; Finnie, JW; Keefe, DM; Mayo, BJ; Plews, E; Stringer, AM | 1 |
| Bosserman, L; DeSilvio, ML; Hagan, MK; Hart, L; Mahoney, JM; Nagarwala, Y; Richards, P; Salleh, MN; Waterhouse, DM; Yardley, DA | 1 |
| Ba, Y; Deng, T; Guo, ZQ; Hu, CH; Huang, DZ; Meng, JC; Wan, HP; Wang, ML; Xiong, JP; Xu, N; Yan, Z; Yao, Y; Yu, Z; Yu, ZH; Zhang, Y; Zheng, RS; Zhuang, ZX | 1 |
| Polee, MB; Siersema, PD; Splinter, TA; Stoter, G; Tilanus, HW; Van der Gaast, A; Verweij, J | 1 |
| Periman, P | 1 |
| Calvert, H; Calvert, P; Gallant, G; Ghielmini, M; Gupta, E; Plummer, R; Renard, J; Sessa, C; Voi, M | 1 |
| Antonellini, A; Elfring, GL; Gillenwater, HH; Israel, VK; Locker, PK; Miller, LL; Natale, RB; Sandler, AB; Socinski, MA | 1 |
| Fukuoka, M; Inoue, A; Kunitoh, H; Mori, K; Nukiwa, T; Saijo, N | 1 |
| Armstrong, DK; Davidson, NE; Emens, LA; Fetting, JH; Garrett, E; Kennedy, MJ | 1 |
| Beijnen, JH; Boot, H; Kruijtzer, CM; Lochs, HL; Mathôt, RA; Parnis, FX; Pelgrims, JM; Planting, AS; Rosing, H; Schellens, JH; Schot, ME; Van Tinteren, H; Williams, R | 1 |
| Ando, M; Katsumata, N; Mukai, H; Watanabe, T | 1 |
| Cao, Y; Liu, H; Liu, P; Qiao, X; Tong, F; Wang, S; Yang, D; Zhang, J; Zhou, B | 1 |
| Fujii, T; Komatsu, M; Kumagai, M; Kusuda, T; Naitou, H; Shinkou, S; Takehara, K | 1 |
| Johnson, CS; Muindi, JR; Peng, Y; Potter, DM; Trump, DL | 1 |
| Byun, JR; Cho, SH; Chung, IJ; Kim, HJ; Kim, YK; Lee, JJ; Na, KJ; Song, SY; Yang, DH | 1 |
| Andersen, N; Brandt, D; Davies, MJ; Murren, JR; Nadkarni, R; Parisot, N; Pizzorno, G; Psyrri, D; Rose, M; Rosenfield, AT; Zelterman, D | 1 |
| Ballas, MS; Dennis, PA | 1 |
| Arango, JI; Bradshaw, P; Callander, NS; Freytes, CO; Ochoa-Bayona, JL; Patterson, J; Restrepo, A; Restrepo, MI; Schneider, DL | 1 |
| Ahn, JB; Cho, BC; Choi, HJ; Kim, CB; Kim, JH; Lee, YC; Sohn, JH | 1 |
| Cao, Y; Dong, QM; Jiang, WQ; Li, H; Li, S; Peng, RJ; Shi, YX; Yuan, ZY; Zhou, ZM | 1 |
| Cohen, RB; Cosgriff, TM; Eisenberg, PD; Hainsworth, JD; Healey, D; Langer, CJ; Liau, K; Madajewicz, S; Pierce, K; Simon, GR; Xu, H | 1 |
| Botti, G; Comella, G; Comella, P; D'Aiuto, G; De Rosa, V; Di Bonito, M; Frasci, G; Iodice, G; Rubulotta, MR; Thomas, R | 1 |
| Beer, TM; Garzotto, M; Lin, D; Montgomery, RB; Nelson, PS; Ryan, CW | 1 |
| Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Shirasaka, T; Yamada, Y; Yamamitsu, S | 1 |
| Azzoli, CG; Brower, M; Chia, G; Fiore, J; Hawkins, MJ; Heelan, R; Kris, MG; Miller, VA; Ng, KK; Riely, GJ; Rizvi, NA | 1 |
| Gomella, L; Greenberg, R; Hudes, GR; Khater, C; McAleer, C; Nathan, FE; Stern, C | 1 |
| Barnes, CS; Cowan, KH; Denicoff, AM; Goldspiel, BR; Gossard, MR; Kohler, DR; McCabe, M; Noone, MH; O'Shaughnessy, JA; Tolcher, AW; Zujewski, J | 1 |
| Balis, F; Berg, S; Chow, C; Cowan, KH; Denicoff, A; Fisherman, JS; Goldspiel, B; McCabe, M; Noone, M; O'Shaughnessy, J; Ognibene, FP; Poplack, D; Venzon, D | 1 |
| Armand, JP; Couteau, C; Goncalves, E; Terret, C; Yakendji, K | 1 |
| Ebbert, LP; Edmonson, JH; Gerstner, JB; Jung, SH; McGaw, H; Nascimento, AG | 1 |
| Klaassen, U; Seeber, S | 1 |
| Grinblatt, DL; Malloy, R; Williams, SF; Zimmerman, TM | 1 |
| Aptaker, L; Barakat, RR; Husain, A; Spriggs, DR | 1 |
| Armand, JP; Couteau, C | 1 |
| Candalh, E; Kramar, A; Lebecq, A | 1 |
| Burger, HU; Burris, HA; Drengler, RL; Eckhardt, SG; Griffin, T; Kraynak, M; Moczygemba, J; Reigner, B; Rodrigues, G; Rowinsky, EK; Villalona-Calero, MA; Von Hoff, DD; Weiss, GR | 1 |
| Bartholomeus, S; Bleiberg, H; Brassinne, C; Cazenave, I; de Valeriola, D; Hennebert, P; Kerger, J; Kusenda, Z; Lefresne-Soulas, F; Piccart, M; Selleslags, J; Van Den Neste, E; Wythouck, H | 1 |
| Beijnen, JH; Bult, A; Huizing, MT; Lustig, V; Rodenhuis, S; Rosing, H; Schellens, JH; ten Bokkel Huinink, WW; van Warmerdam, LJ | 1 |
| Casella, G; De Vivo, R; Ferrari, E; Frezza, P; Iodice, F; Perrone, F; Pignata, S; Ricchi, P; Silvestro, G; Tambaro, R; Tramontana, F; Tramontana, S | 1 |
| Budman, D; Kreis, W; Petrylak, D; Savarese, D | 1 |
| Bhupalam, L; Fleming, DR; Glisson, SD; Goldsmith, GH; LaRocca, RV; Michelson, GD | 1 |
| Böhlke, I; Bokemeyer, C; Derigs, G; Hartmann, JT; Kanz, L; Mayer, F; Schröder, M; Von Pawel, J | 1 |
| Blakey, D; Brettell, M; Briggs, P; Chapple, P; Eerhard, S; Gates, P; Januszewicz, EH; Juneja, S; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Seymour, JF; Toner, GC; Wolf, M | 1 |
| Besenval, M; D'Aloisio, S; Daigneault, L; Eisenhauer, E; Fisher, B; Forand, D; Gelmon, KA; Génier, L; Latreille, J; Lebecq, A; Tolcher, A; Vernillet, L | 1 |
| Agelaki, S; Georgoulias, V; Kakolyris, S; Kourousis, CH; Malliotakis, P; Mavroudis, D; Sarra, E; Souglakos, J | 1 |
| Barbieri, F; Bearz, A; Ceresoli, GL; Favaretto, A; Frustaci, S; Ghiotto, C; Oniga, F; Paccagnella, A; Schiavon, S; Villa, E | 1 |
| Atkinson, R; Coleman, R; Crawford, M; Cruickshank, M; Eggleton, P; Fleming, D; Graham, J; Kaye, SB; Parkin, D; Paul, J; Reed, NS; Vasey, PA | 1 |
| Elfring, GL; Hanover, CK; Israel, VK; Locker, PK; Miller, LL; Natale, RB; Pirotta, N; Sandler, AB; Socinski, MA | 1 |
| Eichelmann, K; Fahlke, J; Gebauer, T; Kettner, E; Kröning, H; Lippert, H; Meyer, F; Ridwelski, K | 1 |
| Aletti, G; Beatrice, S; Carnelli, M; Ferrari, A; Frigerio, L; Garavaglia, E; Mangili, G | 1 |
| Kanno, H; Kuzuta, T; Matsui, H; Seki, K; Sekiya, S; Yamazawa, K | 1 |
| Doi, S; Fukuda, M; Kanda, T; Kawabata, S; Kinoshita, A; Kohno, S; Nagashima, S; Nakamura, Y; Narasaki, F; Oka, M; Soda, H; Suenaga, M; Takatani, H; Tsurutani, J | 1 |
| Davis, JA; Kaye, SB; O'Neill, VJ; Paul, J; Reed, NS; Vasey, PA | 1 |
| Bedikian, A; Desai, N; Ellerhorst, JA; Esmaeli, B; Hortobagyi, GN; Ibrahim, NK; Legha, S; Ring, SE; Rivera, E; Soon-Shiong, P; Theriault, RL | 1 |
| Fujita, A; Hoshino, H; Ohkubo, T; Sekine, K; Tagaki, S; Takabatake, H | 1 |
2 review(s) available for paclitaxel and Diarrhea
| Article | Year |
|---|---|
[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
Topics: Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Irinotecan; Loperamide; Male; Neoplasms; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Topoisomerase I Inhibitors | 1996 |
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Enzyme Inhibitors; Etoposide; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
69 trial(s) available for paclitaxel and Diarrhea
| Article | Year |
|---|---|
Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA).
Topics: Acrylamides; Albumins; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Diarrhea; Female; Humans; Incidence; Neoplasm Staging; Paclitaxel; Prospective Studies; Quality of Life; Receptor, ErbB-2; Treatment Outcome | 2022 |
HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Docetaxel; Female; Humans; Paclitaxel; Quality of Life; Receptor, ErbB-2; Taxoids; Trastuzumab | 2022 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Double-Blind Method; Female; Humans; Ipilimumab; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neutropenia; Outcome Assessment, Health Care; Paclitaxel; Proportional Hazards Models | 2017 |
Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Progression-Free Survival; Severity of Illness Index; Thrombocytopenia; Triple Negative Breast Neoplasms | 2018 |
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Female; Humans; Hypokalemia; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Receptor, ErbB-2; Receptor, ErbB-3 | 2018 |
A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cohort Studies; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Letrozole; Middle Aged; Nausea; Paclitaxel; Sulfonamides; Trastuzumab | 2018 |
Assessment of the administration of maropitant and loperamide to dogs with cancer for the prevention and reduction of adverse effects associated with the administration of paclitaxel.
Topics: Animals; Antidiarrheals; Antiemetics; Antineoplastic Agents, Phytogenic; Diarrhea; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Loperamide; Male; Neoplasms; Paclitaxel; Quinuclidines; Random Allocation; Vomiting | 2019 |
Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Paclitaxel; Quality of Life; Treatment Outcome | 2013 |
Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Diarrhea; Drug Administration Schedule; Drug Eruptions; Female; Humans; Incidence; Lapatinib; Logistic Models; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2; Time Factors; Trastuzumab | 2013 |
Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Double-Blind Method; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Niacinamide; Oligonucleotides; Paclitaxel; Proportional Hazards Models; Treatment Outcome; Young Adult | 2014 |
Exploration of paclitaxel (Taxol) as a treatment for malignant tumors in cats: a descriptive case series.
Topics: Animals; Antineoplastic Agents; Cat Diseases; Cats; Diarrhea; Drug Administration Schedule; Infusions, Intravenous; Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia; Vomiting | 2015 |
Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer.
Topics: Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Diarrhea; Female; Hemoglobins; Humans; Japan; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinazolines; Receptor, ErbB-2; Survival Rate | 2015 |
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cytoreduction Surgical Procedures; Diarrhea; Disease Progression; Disease-Free Survival; Double-Blind Method; Fallopian Tube Neoplasms; Female; Humans; Indoles; Intention to Treat Analysis; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Response Evaluation Criteria in Solid Tumors; Thrombocytopenia; Young Adult | 2016 |
Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotoxicity; Cisplatin; Cyclophosphamide; Diarrhea; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Receptor, ErbB-2; Stroke Volume; Taxoids; Trastuzumab | 2016 |
HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Diarrhea; Docetaxel; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Proanthocyanidins; Prognosis; Quality of Life; Taxoids; Trastuzumab; Young Adult | 2017 |
Carboplatin plus Weekly Paclitaxel Combined with Bevacizumab as First-line Treatment for Non-small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Febrile Neutropenia; Female; Humans; Infections; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome; Vomiting | 2017 |
Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Diarrhea; Exanthema; Fatigue; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neutropenia; Paclitaxel; Pain; Skin Neoplasms; Survival Rate; Tumor Burden | 2009 |
A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Combined Modality Therapy; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lenalidomide; Male; Middle Aged; Nausea; Neutropenia; Orchiectomy; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids; Thalidomide; Treatment Outcome; Vomiting | 2010 |
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diarrhea; Dose-Response Relationship, Drug; Doxorubicin; Feasibility Studies; Female; Filgrastim; Follow-Up Studies; Gene Amplification; Granulocyte Colony-Stimulating Factor; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pilot Projects; Polyethylene Glycols; Quinazolines; Receptor, ErbB-2; Recombinant Proteins; Survival Rate; Trastuzumab; Treatment Outcome | 2010 |
Prospective phase I-II trial of helical tomotherapy with or without chemotherapy for postoperative cervical cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Chemoradiotherapy; Chronic Disease; Cisplatin; Diarrhea; Disease-Free Survival; Feasibility Studies; Female; Follow-Up Studies; Humans; Lymph Nodes; Middle Aged; Nausea; Neoplasm Invasiveness; Organs at Risk; Paclitaxel; Prospective Studies; Radiotherapy, Intensity-Modulated; Tumor Burden; Uterine Cervical Neoplasms; Vesicovaginal Fistula | 2011 |
Efficacy of concurrent chemoradiotherapy plus adjuvant chemotherapy on advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Dose Fractionation, Radiation; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life; Remission Induction; Survival Rate; Taxoids; Uterine Cervical Neoplasms; Vomiting | 2010 |
Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Phytogenic; Chemoradiotherapy; Diarrhea; Drug Administration Schedule; Humans; Leukopenia; Male; Middle Aged; Neoplasm Grading; Paclitaxel; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy Dosage; Survival Analysis; Urination Disorders | 2012 |
Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Diarrhea; Female; Heart Function Tests; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pilot Projects; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2012 |
Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Area Under Curve; Asian People; Breast Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Exanthema; Female; Humans; Japan; Male; Metabolic Clearance Rate; Middle Aged; Nanoparticles; Nausea; Neoplasm Metastasis; Neoplasms; Paclitaxel; Treatment Outcome | 2012 |
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lapatinib; Liver; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2012 |
Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Combined Modality Therapy; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Mammalian orthoreovirus 3; Middle Aged; Nausea; Neoplasms; Oncolytic Virotherapy; Oncolytic Viruses; Paclitaxel; Stomatitis; Treatment Outcome | 2012 |
Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Nausea; Paclitaxel; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2013 |
[A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Prospective Studies; Remission Induction; Stomach Neoplasms; Survival Rate; Tegafur | 2012 |
Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Diarrhea; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Nervous System Diseases; Paclitaxel; Survival Analysis; Treatment Outcome | 2002 |
Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Molecular Structure; Neoplasms; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 2002 |
Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Survival Analysis; Vomiting | 2002 |
Phase I trial of weekly docetaxel in elderly patients with non-small cell lung cancer.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Diarrhea; Docetaxel; Drug Administration Schedule; Female; Humans; Infections; Lung Neoplasms; Male; Neutropenia; Paclitaxel; Taxoids | 2002 |
A phase I toxicity and feasibility trial of sequential dose-dense induction chemotherapy with doxorubicin, paclitaxel, and 5-fluorouracil followed by high dose consolidation for high-risk primary breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Diarrhea; Doxorubicin; Drug Administration Schedule; Erythema; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Sleep Wake Disorders; Time Factors | 2002 |
Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Cyclosporine; Diarrhea; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Stomach Neoplasms; Treatment Outcome; Vomiting | 2003 |
[Clinical evaluation of effects from neoadjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer--comparative study of treatment with 2 and 4 cycles].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Chemotherapy, Adjuvant; Diarrhea; Drug Administration Schedule; Epirubicin; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neurotoxicity Syndromes; Paclitaxel | 2004 |
Pharmacokinetics of liquid calcitriol formulation in advanced solid tumor patients: comparison with caplet formulation.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biological Availability; Calcitriol; Calcium Channel Agonists; Capsules; Dexamethasone; Diarrhea; Humans; Male; Paclitaxel; Pharmaceutical Solutions; Prostatic Neoplasms | 2005 |
Bi-weekly chemotherapy of paclitaxel and cisplatin in patients with metastatic or recurrent esophageal cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Diarrhea; Esophageal Neoplasms; Fatigue; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Thrombocytopenia; Time Factors; Treatment Outcome; Vomiting | 2005 |
Evaluation of irinotecan plus paclitaxel in patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Analysis; Time Factors | 2005 |
Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mucositis; Multivariate Analysis; Neutropenia; Paclitaxel; Prognosis; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Exanthema; Female; Gastrointestinal Diseases; Half-Life; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Thiazoles; Treatment Outcome; Urea | 2007 |
Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Diarrhea; Drug Administration Schedule; Epirubicin; Fatigue; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Middle Aged; Neutropenia; Paclitaxel; Patient Compliance; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2006 |
Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Diethylstilbestrol; Drug Administration Schedule; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome; Tubulin Modulators; Venous Thrombosis | 2007 |
Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Anemia; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Survival Rate | 2008 |
Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Estramustine; Fatigue; Hematologic Diseases; Hormones; Humans; Male; Nausea; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome | 1995 |
Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Cyclophosphamide; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Hypersensitivity; Equipment Failure; Erythrocyte Transfusion; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematuria; Home Infusion Therapy; Humans; Mesna; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1996 |
Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Heart; Humans; Middle Aged; Paclitaxel; Thrombocytopenia | 1996 |
[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
Topics: Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Irinotecan; Loperamide; Male; Neoplasms; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Topoisomerase I Inhibitors | 1996 |
Phase II study of docetaxel in advanced soft tissue sarcomas.
Topics: Adult; Aged; Alopecia; Anorexia; Antiemetics; Antineoplastic Agents, Phytogenic; Cause of Death; Dexamethasone; Diarrhea; Diphenhydramine; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leiomyosarcoma; Leukopenia; Male; Middle Aged; Nausea; Paclitaxel; Patient Selection; Premedication; Remission Induction; Sarcoma; Taxoids; Uterine Neoplasms; Vomiting | 1996 |
Metastatic breast cancer: treatment with fluorouracil-based combinations.
Topics: Adult; Aged; Anemia; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Nausea; Neutropenia; Paclitaxel; Thrombocytopenia; Treatment Outcome | 1997 |
A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Breast Neoplasms; Carcinoma; Cohort Studies; Cyclophosphamide; Diarrhea; Esophagitis; Female; Hematopoietic Stem Cell Transplantation; Hemorrhage; Humans; Incidence; Infusions, Intravenous; Lung Diseases; Middle Aged; Neoplasm Staging; Paclitaxel; Pulmonary Alveoli; Remission Induction; Stomatitis; Survival Rate; Thiotepa; Transplantation, Autologous | 1998 |
Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bilirubin; Capecitabine; Cohort Studies; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia | 1999 |
A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Methylprednisolone; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Taxoids | 2000 |
Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion.
Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Alopecia; Antineoplastic Agents, Phytogenic; Area Under Curve; Aspartate Aminotransferases; Breast Neoplasms; Diarrhea; Docetaxel; Fatigue; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Mouth Mucosa; Neoplasms; Neutropenia; Paclitaxel; Stomatitis; Taxoids; Time Factors | 2000 |
Phase I study with weekly cisplatin-paclitaxel and concurrent radiotherapy in patients with carcinoma of the cervix uteri.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Taxoids; Uterine Cervical Neoplasms | 2000 |
Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Deoxycytidine; Diarrhea; Esophageal Neoplasms; Exanthema; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neoplasms, Unknown Primary; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Paresthesia; Urinary Bladder Neoplasms; Vomiting | 2000 |
UFT/leucovorin plus weekly paclitaxel in the treatment of solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Fatigue; Female; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasms; Paclitaxel; Tegafur; Uracil | 2000 |
Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diarrhea; Disease Progression; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lung Diseases, Interstitial; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Recombinant Proteins; Remission Induction; Stomatitis; Survival Analysis; Taxoids; Thiotepa; Thrombocytopenia; Transplantation Conditioning | 2000 |
Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2000 |
A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fever; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Salvage Therapy; Taxoids | 2000 |
Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced non-small-cell lung cancer. Gruppo Studio Tumori Polmonari Veneto (GSTPV).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Diarrhea; Disease-Free Survival; Female; Fever; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Survival Analysis; Treatment Outcome | 2000 |
Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Constipation; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Fatigue; Female; Hematologic Diseases; Humans; Middle Aged; Nausea; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vomiting | 2001 |
Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel | 2001 |
Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Docetaxel; Female; Humans; Leukopenia; Male; Middle Aged; Paclitaxel; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Concomitant radiotherapy and paclitaxel for high-risk endometrial cancer: first feasibility study.
Topics: Aged; Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Diarrhea; Drug Administration Schedule; Drug Eruptions; Endometrial Neoplasms; Feasibility Studies; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation Injuries; Radiation-Sensitizing Agents; Radiodermatitis; Radiotherapy; Radiotherapy, Adjuvant; Risk Factors | 2001 |
Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dermatitis; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia | 2001 |
A dose-finding study of carboplatin-epirubicin-docetaxel in advanced epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Stomatitis; Taxoids | 2002 |
Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Area Under Curve; Castor Oil; Chemistry, Pharmaceutical; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Nervous System Diseases; Paclitaxel; Particle Size; Stomatitis; Taxoids; Treatment Outcome | 2002 |
Phase I study of carboplatin, irinotecan and docetaxel on a divided schedule with recombinant human granulocyte colony stimulating factor support in patients with stage IIIB or IV non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Recombinant Proteins; Taxoids | 2002 |
22 other study(ies) available for paclitaxel and Diarrhea
| Article | Year |
|---|---|
Efficacy and Side Effects of Irinotecan Combined with Nedaplatin versus Paclitaxel Combined with Cisplatin in Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer and Tumor Marker Analysis: Based on a Retrospective Analysis.
Topics: Abdominal Pain; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic Antigen; Case-Control Studies; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Exanthema; Female; Humans; Hyperglycemia; Irinotecan; Nausea; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Retrospective Studies; Uterine Cervical Neoplasms; Vomiting | 2022 |
Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study).
Topics: Adult; Aged; Albumins; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neutropenia; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Paclitaxel-Associated Diarrhea in a 58-Year-Old Woman.
Topics: Antineoplastic Agents, Phytogenic; Biopsy; Colon; Diarrhea; Female; Humans; Middle Aged; Paclitaxel; Pancreatic Neoplasms | 2019 |
A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Computer Simulation; Diarrhea; Female; Humans; Markov Chains; Models, Biological; Neoplasm Metastasis; Paclitaxel | 2018 |
Effect of the weekly administration of liposome-Paclitaxel combined with s-1 on advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Liposomes; Male; Middle Aged; Neutropenia; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Treatment Outcome | 2014 |
Determining the mechanisms of lapatinib-induced diarrhoea using a rat model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease Models, Animal; ErbB Receptors; Goblet Cells; Intestinal Mucosa; Intestines; Lapatinib; Male; Paclitaxel; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Wistar; Receptor, ErbB-2 | 2014 |
Squamous cell carcinoma arising in a mature cystic teratoma invading the sigmoid colon: a rare presentation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Diagnosis, Differential; Diarrhea; Female; Gastrointestinal Hemorrhage; Humans; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel; Peritonitis; Sigmoid Neoplasms; Teratoma; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Toxicity of intraperitoneal chemotherapy and risk factors for severe toxicity in optimally debulked ovarian cancer patients.
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Catheter Obstruction; Catheters, Indwelling; Chemotherapy-Induced Febrile Neutropenia; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Diarrhea; Disease-Free Survival; Female; Humans; Ileus; Infusions, Parenteral; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Risk Factors; Survival Rate; Vomiting; Withholding Treatment | 2015 |
Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Disease Progression; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Follow-Up Studies; Humans; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Netherlands; Paclitaxel; Propensity Score; Thromboembolism | 2017 |
Breast cancer: complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Diarrhea; Female; Heart Function Tests; Humans; Hypothyroidism; Indoles; Lymphatic Metastasis; Middle Aged; Paclitaxel; Pyrroles; Remission Induction; Sunitinib; Trastuzumab | 2010 |
Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease Models, Animal; Lapatinib; Male; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Wistar; Receptor Protein-Tyrosine Kinases | 2012 |
Antibiotic-associated diarrhea.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Diarrhea; Enterocolitis, Pseudomembranous; Humans; Methotrexate; Paclitaxel | 2002 |
Unknown primary carcinoma: a feasibility assessment of combination chemotherapy with cisplatin and docetaxel.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Diarrhea; Docetaxel; Drug Hypersensitivity; Feasibility Studies; Female; Humans; Male; Middle Aged; Nausea; Neoplasms, Unknown Primary; Neutropenia; Paclitaxel; Patient Compliance; Prospective Studies; Severity of Illness Index; Taxoids; Treatment Outcome; Vomiting | 2003 |
[Paclitaxel plus carboplatin in ovarian cancer-comparison of adverse effects between monthly and weekly administration].
Topics: Adult; Aged; Anorexia; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dexamethasone; Diarrhea; Diphenhydramine; Drug Administration Schedule; Female; Humans; Leukopenia; Middle Aged; Nausea; Ovarian Neoplasms; Paclitaxel; Ranitidine; Retrospective Studies; Thrombocytopenia | 2004 |
A slow disengagement from platinum-based chemotherapy for patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Maximum Tolerated Dose; Neutropenia; Paclitaxel; Platinum; Survival Rate; Time Factors | 2005 |
Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma.
Topics: Adult; Aged; Cephalosporins; Clostridioides difficile; Diarrhea; Enterocolitis, Pseudomembranous; Female; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Mobilization; Humans; Incidence; Lymphoma; Male; Middle Aged; Multiple Myeloma; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Risk Factors; Transplantation, Autologous; Vancomycin | 2006 |
[Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mucositis; Neoplasm Staging; Paclitaxel; Stomach Neoplasms; Young Adult | 2006 |
[The second report from Sapporo Tsukisamu hospital--chemotherapy for patients with advanced colorectal cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Nausea; Paclitaxel; Stomatitis; Survival Rate; Vomiting, Anticipatory | 2007 |
Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens.
Topics: Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Diarrhea; Female; Gastrointestinal Diseases; Genital Neoplasms, Female; Humans; Middle Aged; Paclitaxel; Retrospective Studies | 1998 |
Continual reassessment methods in phase I trials of the combination of two drugs in oncology.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Camptothecin; Clinical Trials, Phase I as Topic; Computer Simulation; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Humans; Irinotecan; Likelihood Functions; Neoplasms; Neutropenia; Paclitaxel; Retrospective Studies; Taxoids | 1999 |
Colitis and docetaxel-based chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Colitis; Diarrhea; Docetaxel; Estramustine; Female; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids; Vinblastine; Vinorelbine | 2000 |
Life-threatening Clostridium difficile-associated diarrhea induced by paclitaxel-carboplatin combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clostridioides difficile; Diarrhea; Endometrial Neoplasms; Enterocolitis, Pseudomembranous; Female; Humans; Middle Aged; Paclitaxel | 2001 |